528 related articles for article (PubMed ID: 30376889)
1. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers.
Hale VL; Jeraldo P; Chen J; Mundy M; Yao J; Priya S; Keeney G; Lyke K; Ridlon J; White BA; French AJ; Thibodeau SN; Diener C; Resendis-Antonio O; Gransee J; Dutta T; Petterson XM; Sung J; Blekhman R; Boardman L; Larson D; Nelson H; Chia N
Genome Med; 2018 Oct; 10(1):78. PubMed ID: 30376889
[TBL] [Abstract][Full Text] [Related]
2. Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers.
Li J; Guo Y; Liu J; Guo F; Du L; Yang Y; Li X; Ma Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597851
[TBL] [Abstract][Full Text] [Related]
3. LC‑MS/MS metabolome analysis detects the changes in the lipid metabolic profiles of dMMR and pMMR cells.
Peng W; Tan S; Xu Y; Wang L; Qiu D; Cheng C; Lin Y; Liu C; Li Z; Li Y; Zhao Y; Li Q
Oncol Rep; 2018 Aug; 40(2):1026-1034. PubMed ID: 29989648
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota distinct between colorectal cancers with deficient and proficient mismatch repair: A study of 230 CRC patients.
Jin M; Wu J; Shi L; Zhou B; Shang F; Chang X; Dong X; Deng S; Liu L; Cai K; Nie X; Zhang T; Fan J; Liu H
Front Microbiol; 2022; 13():993285. PubMed ID: 36312959
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
[TBL] [Abstract][Full Text] [Related]
6. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J
PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813
[TBL] [Abstract][Full Text] [Related]
7. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
[TBL] [Abstract][Full Text] [Related]
8. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
[TBL] [Abstract][Full Text] [Related]
9. [Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer].
Tang XJ; Yang MY; Zhu LZ; Xu D; Yuan Y
Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1088-1093. PubMed ID: 34695900
[No Abstract] [Full Text] [Related]
10. The risk of developing a mismatch repair deficient colorectal cancer after undergoing cholecystectomy.
Halldorsson MO; Hauptmann M; Snaebjornsson P; Haraldsdóttir KH; Aspelund T; Gudmundsson EF; Gudnason V; Jonasson JG; Haraldsdottir S
Scand J Gastroenterol; 2018 Aug; 53(8):972-975. PubMed ID: 30010450
[TBL] [Abstract][Full Text] [Related]
11. LDH-A negatively regulates dMMR in colorectal cancer.
Zhang Y; Li J; Wang B; Chen T; Chen Y; Ma W
Cancer Sci; 2021 Aug; 112(8):3050-3063. PubMed ID: 34110068
[TBL] [Abstract][Full Text] [Related]
12. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
[TBL] [Abstract][Full Text] [Related]
13. Tumor Budding
Karlberg M; Stenstedt K; Hallström M; Ragnhammar P; Lenander C; Edler D
Anticancer Res; 2018 Aug; 38(8):4713-4721. PubMed ID: 30061240
[TBL] [Abstract][Full Text] [Related]
14. Intertumoral Heterogeneity of CD3
Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
16. Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
Chen X; Yang Z; Feng J; Duan T; Pan T; Yan L; Jin T; Xiang Y; Zhang M; Chen P; Wang W; Zhang R; Chen B; Zhao L; Xie T; Sui X
Cancer Med; 2021 Jan; 10(1):317-324. PubMed ID: 33174323
[TBL] [Abstract][Full Text] [Related]
17. Different surgical outcome and follow-up status between dMMR and pMMR colorectal cancer patients who fulfilled with Amsterdam-II criteria.
Sun CY; Chiang JM; Chen TC; Hung HY; You JF
World J Surg Oncol; 2020 Aug; 18(1):195. PubMed ID: 32767993
[TBL] [Abstract][Full Text] [Related]
18. The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer.
Sillo TO; Beggs AD; Middleton G; Akingboye A
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982838
[TBL] [Abstract][Full Text] [Related]
19. Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer.
Yang Y; Misra BB; Liang L; Bi D; Weng W; Wu W; Cai S; Qin H; Goel A; Li X; Ma Y
Theranostics; 2019; 9(14):4101-4114. PubMed ID: 31281534
[No Abstract] [Full Text] [Related]
20. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
